Legend Biotech

What Legend Biotech does

Legend Biotech is a global, commercial-stage biopharmaceutical company that develops and commercializes novel cell therapies for oncology. Founded in 2014 and headquartered in Bridgewater, New Jersey, the company operates through subsidiaries across the United States, Europe (Belgium, Ireland), and China (Nanjing), with approximately 3,000 employees worldwide. Legend is a majority-owned affiliate of GenScript Biotech Corporation and is publicly traded on NASDAQ under the ticker LEGN.

The company's core product is CARVYKTI (ciltacabtagene autoleucel), a BCMA-directed autologous CAR-T cell therapy approved by the FDA in February 2022 and the EMA in May 2022 for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy. CARVYKTI is commercialized globally through a 2017 strategic partnership with Johnson & Johnson's Janssen Biotech, with the therapy available at 294 treatment sites across 14 markets and 18 countries, having treated more than 10,000 patients worldwide. Legend operates four proprietary technology platforms — autologous CAR-T, allogeneic non-gene-editing CAR-T, CAR-γδ T, and CAR-NK — and is advancing a pipeline including LB2501 (in vivo CD19/CD20 dual-targeting CAR-T for NHL), LB2102 (DLL3-targeted CAR-T for small cell lung cancer, partnered with Novartis), LB1908 (Claudin 18.2-targeted CAR-T for gastroesophageal cancer), and LUCAR-G39D (allogeneic CD20/CD19 dual-CAR γδ T cells).

Legend Biotech's revenue is generated primarily through collaboration revenue from the Johnson & Johnson partnership for CARVYKTI, with FY2025 collaboration revenue of approximately $1.029 billion (up 64% year-over-year) and Q1 2026 revenue of $305.1 million. CARVYKTI net trade sales (jointly reported with J&J) reached approximately $1.9 billion in FY2025 and $597 million in Q1 2026 (up 62% YoY). Pricing follows the high-cost specialty CAR-T model, typically $400,000–$500,000+ per one-time infusion, with Chinese listings at CNY 999,000–CNY 1.3 million. The company achieves revenue through treatment center distribution rather than direct consumer sales, with manufacturing currently at 10,000 annualized doses and scaling toward 20,000 doses annually. CARVYKTI achieved product-level profitability in 2025 and Legend targets company-wide profitability in 2026.

Name

Legend Biotech

Legal name

Legend Biotech USA Inc.

Website

https://legendbiotech.com

Company type

Public

Founded year

2014

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Legend Biotech is a global commercial-stage biopharmaceutical company developing CAR-T cell therapies for oncology, anchored by FDA-approved CARVYKTI for relapsed/refractory multiple myeloma commercialized with Johnson & Johnson, with a pipeline targeting hematologic malignancies and solid tumors across four proprietary cell therapy platforms.

Ownership category

akta.pro rank

Product category

Cell Therapy Pharmaceuticals — Oncology Biologics

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Scientific Research and Development Services (5417)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Cell Therapy Developers (Autologous) (HLAAABAA)

akta.pro secondary industries

Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL), Cell Therapy Developers (Allogeneic/Off-the-shelf) (HLAAABAB), Oncology Gene Therapies (incl. oncolytic vectors & gene-modified approaches) (HLAAACAF)

Keywords

• CAR-T cell therapy
• Oncology therapeutics
• Hematologic malignancies
• Cell therapy platforms
• Biopharmaceutical products

Headquarters

HQ city

Piscataway

HQ country

United States

HQ region

North America

Offices7 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales

Revenue model

1. CARVYKTI Product Sales: Revenue from global sales of CARVYKTI (ciltacabtagene autoleucel), a BCMA-directed CAR-T cell therapy for multiple myeloma. Q4 2025 net trade sales of $555 million; full year 2025 net trade sales of approximately $1.9 billion. Revenue grew 64% year-over-year in 2025 to $1.03 billion.
2. Collaboration Revenue from Johnson & Johnson: Legend Biotech shares collaboration revenue with Janssen Biotech (Johnson & Johnson) for the global development and commercialization of CARVYKTI. The partnership involves co-development, cost-sharing, and profit-sharing arrangements.

Pricing tiers

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Core offering

Legend Biotech develops and commercializes novel cell therapies for oncology, with a primary focus on autologous CAR-T cell therapies. Its lead product, CARVYKTI (ciltacabtagene autoleucel), is a BCMA-directed CAR-T therapy approved for the treatment of adult patients with relapsed or refractory multiple myeloma. The company also maintains a pipeline of investigational cell therapies including in vivo CAR-T, DLL3-targeted CAR-T, Claudin 18.2-targeted CAR-T, and allogeneic gamma-delta T cell therapies for hematologic malignancies and solid tumors.

Product overview

Legend Biotech is a global, commercial-stage biotechnology company and the largest standalone cell therapy company, developing a portfolio of cell therapy products and technology platforms. The company's lead commercial product is CARVYKTI (ciltacabtagene autoleucel), a BCMA-directed CAR-T therapy for multiple myeloma approved in the US (2022) and EU (2022), marketed in partnership with Johnson & Johnson's Janssen Biotech. Legend Biotech's pipeline includes multiple investigational CAR-T candidates: LB2501 (in vivo CD19/CD20 dual-targeting CAR-T for NHL in Phase 1), LB2102 (DLL3-targeted CAR-T for small cell lung cancer in Phase 1, partnered with Novartis), LB1908 (Claudin 18.2-targeted CAR-T for gastroesophageal cancer in Phase 1), and LUCAR-G39D (allogeneic CD20/CD19 dual-CAR gamma-delta T cells for NHL in Phase 1). The company is built on four technology platforms: autologous CAR-T, CAR-γδ T, CAR-NK, and non-gene-editing universal CAR-T. Legend Biotech operates as an end-to-end cell therapy company with capabilities spanning discovery through commercialization.

Differentiator

Problem solved

Functional benefit

Brands

• CARVYKTI: CAR-T cell therapy product (ciltacabtagene autoleucel) for the treatment of relapsed or refractory multiple myeloma, developed in partnership with Johnson & Johnson

Products and services

• CARVYKTI (ciltacabtagene autoleucel) A BCMA-directed chimeric antigen receptor T cell (CAR-T) therapy administered as a one-time infusion for the treatment of adult patients with relapsed or refractory multiple myeloma who have received four or more prior lines of therapy. Developed and commercialized in partnership with Johnson & Johnson's Janssen Biotech.
• LB2501 Investigational in vivo CD19/CD20 dual-targeting CAR-T cell therapy in Phase 1 development for relapsed or refractory B-cell non-Hodgkin lymphoma. Achieved 100% objective response rate and 83.3% complete response rate at dose level 2 with no dose-limiting toxicities or serious adverse events, and does not require lymphodepletion.
• LB2102 Investigational DLL3-targeted CAR-T cell therapy armored with dominant-negative TGF-beta receptor 2 (dnTGFBR2) in Phase 1 development for relapsed or refractory small cell lung cancer and large-cell neuroendocrine carcinoma. Demonstrated 28.6% objective response rate and 78.6% disease control rate at higher dose levels. Licensed to Novartis Pharma AG for worldwide development and commercialization (Legend retains US Phase 1 trial).
• LB1908 Investigational autologous Claudin 18.2-targeted chimeric antigen receptor T-cell product in Phase 1 development for advanced gastroesophageal adenocarcinoma.
• LUCAR-G39D Novel anti-CD20/CD19 dual-CAR allogeneic gamma-delta T cell therapy in Phase 1 development for relapsed/refractory B-cell non-Hodgkin lymphoma, leveraging the allogeneic CAR-γδ T platform.

Quantifiable outcome

• CARVYKTI achieved 5-year overall survival rates exceeding 85% in CARTITUDE-1 patients
• +4 more outcomes

Named customers2 records

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Three partnerships are on record, tiered major and core.

• Novartis Pharma AGmajorOEM/ Whitelabel/ Licensing Partner · 1 November 2023License agreement for DLL3-targeted CAR-T therapies. Legend Biotech retains responsibility for the ongoing US Phase 1 trial while Novartis holds exclusive worldwide rights for other development, manufacturing, and commercialization of DLL3-targeted CAR-T therapies. LB2102 program is being advanced under this agreement.
• Johnson & Johnson (Janssen Biotech)coreStrategic or Co-development Partner · 1 January 2017Strategic collaboration with Janssen Biotech to co-develop and commercialize CARVYKTI (ciltacabtagene autoleucel), Legend's BCMA-directed CAR-T cell therapy for multiple myeloma. Partnership involves global co-development, cost-sharing, and profit-sharing arrangements. J&J leads global commercialization while Legend maintains manufacturing responsibilities in partnership facilities in New Jersey and Belgium.
• GenScript Biotech CorporationcoreOthersGenScript Biotech Corporation is the parent company of Legend Biotech. Legend Biotech Corporation is listed on NASDAQ and operates as an independent entity with GenScript as majority shareholder. Frank Zhang serves as Chairman of Legend Biotech and holds leadership positions at GenScript.

Scale indicators15 records

Recent moves11 records

Expansion highlights5 records

Direct peers

• Bristol Myers Squibb: Markets ABECMA (idecabtagene vicleucel), a BCMA-directed CAR-T approved for multiple myeloma — the closest direct competitor to Legend's CARVYKTI in the same indication. BMS is also backing 2seventy bio in patent litigation against Legend.
• 2seventy bio: Discovery and development partner with BMS on ABECMA (BCMA CAR-T for multiple myeloma). Directly competes with Legend in BCMA-directed CAR-T and is the plaintiff in the ongoing CARVYKTI patent dispute at the Unified Patent Court.
• Kite Pharma (Gilead Sciences): Markets YESCARTA and TECARTUS, two approved CAR-T therapies in hematologic malignancies. Kite is a leading CAR-T commercial organization and competes for treatment center capacity and BCMA/BCMA-adjacent patient share.
• Iovance Biotherapeutics: Commercial-stage cell therapy company with FDA-approved tumor-infiltrating lymphocyte (TIL) therapies for solid tumors. Comparable as a focused, commercial-stage cell therapy developer targeting oncology with complex autologous manufacturing.
• Allogene Therapeutics: Clinical-stage allogeneic CAR-T developer. Competes with Legend's allogeneic CAR-γδ T and non-gene-editing universal CAR-T programs in the off-the-shelf CAR-T space.

Broad incumbents

• Novartis: Markets KYMRIAH, the first FDA-approved CAR-T, and holds exclusive worldwide rights (ex-US Phase 1) to Legend's DLL3 CAR-T LB2102 via a 2023 license agreement. A broad-incumbent cell therapy player and partner/peer along the CAR-T value chain.

Emerging players

• Adaptimmune Therapeutics: Developer of cell therapies for solid tumors, including TCR-T cell therapies with comparable patient target populations (e.g., DLL3 in SCLC). Comparable as a cell therapy developer focused on intractable solid tumor indications.
• Caribou Biosciences: Clinical-stage allogeneic CAR-T developer using CRISPR gene editing. Comparable as an emerging allogeneic CAR-T competitor overlapping with Legend's non-gene-editing universal CAR-T platform.
• CRISPR Therapeutics: Gene-edited cell therapy developer (CASGEVY for sickle cell disease, allogeneic CAR-T programs). Comparable as a cell/gene therapy developer pushing novel modalities including gene editing.
• Fate Therapeutics: iPSC-derived off-the-shelf NK and T-cell therapy developer. Comparable as an emerging player in the allogeneic cell therapy space with overlapping CAR-NK and engineered T-cell modalities.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/LegendBiotech
• LinkedInlinkedin.com/company/legendbiotechco.
• Instagraminstagram.com/legend_biotech

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles15 records

Subsidiaries9 records

Funding overview

Funding rounds4 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Legend Biotech